MYCOSIS FUNGOIDES
Clinical trials for MYCOSIS FUNGOIDES explained in plain language.
Never miss a new study
Get alerted when new MYCOSIS FUNGOIDES trials appear
Sign up with your email to follow new studies for MYCOSIS FUNGOIDES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody targets Hard-to-Treat skin cancer in first human trial
Disease control Not yet recruitingThis early-phase trial tests a new drug, DT-7012, for people with advanced cutaneous T-cell lymphoma (CTCL) that has not responded to other treatments. The drug is an antibody designed to seek out and destroy cancer cells in the skin while also helping the immune system fight the…
Matched conditions: MYCOSIS FUNGOIDES
Phase: EARLY_PHASE1 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated May 17, 2026 02:17 UTC
-
New targeted therapy aims to control rare skin cancer in patients who failed other treatments
Disease control Not yet recruitingThis study tests an experimental drug, VG712, in people with mycosis fungoides (a rare skin lymphoma) that has not responded to at least two prior treatments. The drug works by killing certain immune cells that drive the disease. About 386 adults will be randomly assigned to rece…
Matched conditions: MYCOSIS FUNGOIDES
Phase: PHASE2 • Sponsor: Virogen Biotechnology Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC